At a glance Drug / evolocumab (Repatha), a PCSK9-inhibitor biologic antibody Supplement / glutathione (oral, liposomal, or IV forms) Known interaction / none documented in published literature or FDA label Interaction type / not applicable, no shared metabolic pathway identified Evolocumab clearance / proteolytic catabolism, not CYP450 or GSH-dependent Glutathione CYP effect / negligible at typical oral doses (250 to 1,000 mg/day) LDL-C reduction with evolocumab / up to 59% vs
Lifestyle modification remains fundamental, and patients should be encouraged to maintain healthy eating patterns, regular physical activity, and adequate hydration (individualised to their clinical situation, particularly for those with heart failure or kidney disease)
Sermorelin - for adults experiencing symptoms consistent with age-related growth hormone decline who are interested in a GHRH-based approach rather than direct hormone replacement
Injectable glutathione represents a clinically-oriented approach to wellness optimization, offering targeted cellular support that addresses foundational health concerns including environmental toxin exposure, immune resilience, and age-related oxidative stress
doi: Sforzo, G.A., Gordon, N.F., Peeke, P.M
